Long-term effects of mirikizumab in the treatment of Crohn's disease

Milikizumab (Mirikizumab), as a biological agent that has rapidly attracted global attention in recent years, has brought new treatment ideas to the long-term management of Crohn's disease (CD) with its precise blocking effect on the IL-23 pathway. Crohn's disease is a chronic and relapsing immune-mediated intestinal inflammation. Its essence is that the intestinal mucosa continues to suffer inflammatory damage caused by excessive activation of the immune system, and the IL-23 pathway plays a key regulatory role in this type of inflammatory response. Therefore, once this pathway is inhibited, long-term inflammation of the intestinal mucosa can be effectively controlled, helping to reduce the frequency of recurrence and delay the progression of intestinal structural damage.

From a long-term efficacy perspective, research data shows that maintenance treatment with militizumab can allow many patients to remain stable on the basis of inflammation relief. Especially during the long-term observation period, its trend in improving core symptoms such as abdominal pain, diarrhea, and weight loss is relatively obvious. More importantly, long-term use does not show rapid fading of efficacy, which is particularly critical for Crohn's disease, which essentially requires long-term immune regulation. In addition, after some patients took militizumab for a period of time, the inflammatory signals in the intestinal mucosa were weakened, and the changes in the intestinal wall reflected by imaging and endoscopy also appeared in a more stable state, which indirectly means that long-term drug management can help slow down the progression of the disease to intestinal stenosis or fistulas.

Another highlight of the long-term effects comes from the improvement in patients’ quality of life. Crohn's disease itself is volatile and the frequency of relapses is difficult to predict. Milizumab's stable anti-inflammatory ability during maintenance treatment allows more patients to keep their symptoms under control for a longer period of time, which means that patients' social, work and eating patterns can return to a state closer to health. The risk of side effects is also relatively mild in long-term use, so that the durability of the efficacy will not be hindered by tolerability issues.

Reference materials:https://omvoh.lilly.com/